Drug Approval | May 31, 2021
Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The GMP certificate is valid for three years until April 2024.
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The commercial production in the SML was started in November 1989.
Vijay brings more than 28 years of experience across healthcare, technology, edtech, manufacturing, and global business environments
Subscribe To Our Newsletter & Stay Updated
